Major Haemorrhage Protocol Simulation Training: Emergency Blood Bank Scenarios for UK Biomedical Scientists

Major haemorrhage is one of the most critical emergencies in healthcare, and blood bank scientists play a pivotal role in patient survival. The Major Haemorrhage Protocol (MHP) Simulation Training on PathologyLabTraining provides immersive, scenario-based practice for emergency blood provision. This comprehensive training covers 12 clinical scenarios, from obstetric emergencies to complex haematological cases, preparing you to make rapid, evidence-based decisions under pressure.

What is Major Haemorrhage Protocol?

Major haemorrhage protocol is activated when a patient experiences significant blood loss requiring urgent transfusion support. In UK practice, MHP activation typically occurs when:

• Estimated blood loss exceeds 150 ml/minute
• 50% or more of total blood volume is lost within 3 hours
• Systolic blood pressure falls below 90 mmHg with tachycardia (>110 bpm)
• Clinical teams anticipate ongoing massive transfusion requirements

The blood bank's role in MHP is critical. You must provide compatible blood products rapidly whilst maintaining safety standards, managing limited stock, and communicating effectively with clinical teams. According to SHOT (Serious Hazards of Transfusion) data, approximately 3,000-4,000 MHP activations occur annually across UK hospitals, with obstetric and trauma cases accounting for the majority.

Blood bank responsibilities during MHP include:

• Immediate release of emergency O Negative/O Positive blood
• Rapid crossmatching and antibody screening
• Component preparation (FFP, platelets, cryoprecipitate)
• Stock management and requesting additional supplies
• Communication with clinical teams and porters
• Documentation and traceability

The 12 Clinical Scenarios

Our MHP simulation training covers diverse clinical presentations that blood bank scientists encounter:

Obstetric Emergencies

Postpartum Haemorrhage (PPH) - The most common obstetric MHP trigger, occurring in approximately 1-5% of deliveries. Scenarios include uterine atony, retained placenta, and coagulopathy following PPH.

Placental Abruption - Sudden placental separation causing massive haemorrhage and potential DIC. Time-critical scenarios requiring immediate O Negative blood and fibrinogen replacement.

Trauma Cases

Road Traffic Collision (RTC) - Multi-trauma patients with polytrauma and uncontrolled bleeding. Practice managing unknown blood groups and massive transfusion requirements.

Paediatric Trauma - Age-specific considerations including weight-based dosing, smaller blood volumes, and CMV-negative requirements.

Gastrointestinal Emergencies

Variceal Bleeding - Oesophageal varices in patients with liver disease. Complex scenarios involving coagulopathy, thrombocytopenia, and portal hypertension effects.

Surgical Cases

AAA Repair - Ruptured abdominal aortic aneurysm with catastrophic blood loss. Practice sustained massive transfusion over extended periods.

Liver Transplant - Complex coagulation management during hepatectomy and graft reperfusion. Multi-phase scenarios with changing transfusion requirements.

Cardiac Surgery

Cardiopulmonary Bypass (CPB) - Haemodilution, platelet dysfunction, and heparin anticoagulation creating unique challenges. Post-bypass reversal scenarios with protamine and component therapy.

Neonatal Cases

Exchange Transfusion - Severe neonatal jaundice or haemolytic disease. Calculating exchange volumes, selecting irradiated CMV-negative units, and managing small blood volumes.

Haematological Emergencies

Sickle Cell Crisis - Acute chest syndrome or splenic sequestration in sickle cell patients. HbS-negative requirements and exchange transfusion considerations.

Disseminated Intravascular Coagulation (DIC) - Consumptive coagulopathy with simultaneous bleeding and thrombosis. Complex component replacement balancing.

Complex Cases

Multiple Antibodies - Patients with complex antibody profiles requiring antigen-negative units. Managing limited stock whilst sourcing compatible blood from NHSBT.

Interactive Simulation Features

The MHP simulation provides realistic training through multiple interactive elements:

Real-Time Patient Monitoring

Dynamic vital signs display showing heart rate, blood pressure, oxygen saturation, and estimated blood loss. Parameters deteriorate or improve based on your intervention timing and component selection.

Phone Call Simulations

Receive urgent calls from theatre teams, A&E coordinators, and clinical staff requesting blood products. Practice clear communication, gathering essential clinical information, and providing realistic time estimates.

Blood Bank Stock Management

Track your inventory of O Negative, O Positive, group-specific blood, FFP, platelets, and cryoprecipitate. Make decisions when stock runs low and request emergency supplies from NHSBT.

Sample Analysis Workflow

Process emergency samples with quality checks for correct labelling, sample integrity, and patient identification. Identify pre-analytical errors that could compromise patient safety.

Crossmatch Panel Options

Select appropriate crossmatch methods based on clinical urgency and antibody screen results:

• Electronic Issue - For patients with negative antibody screen and two valid group samples
• Immediate Spin Crossmatch - Rapid compatibility check for urgent requirements
• IAT Crossmatch - Full serological crossmatch for patients with antibodies

UK English Voice Guidance

Audio alerts and voice guidance using authentic UK pronunciation and terminology. Hear realistic MHP activation calls and clinical communications.

Time-Pressure Decision Making

Countdown timers create authentic urgency. Most decisions require response within 30-60 seconds, replicating real emergency conditions.

BCSH Target Parameters

Blood component therapy during MHP aims to maintain specific haematological parameters. These targets are based on British Committee for Standards in Haematology guidelines:

| Parameter | Target | Clinical Significance | |-----------|--------|----------------------| | Haemoglobin | >100 g/L | Oxygen carrying capacity for tissue perfusion | | Platelets | >100 x10⁹/L | Primary haemostasis and clot formation | | Fibrinogen | >2.0 g/L | Critical for stable clot formation | | PT/APTT | <1.5x normal | Adequate coagulation factor levels | | Ionised Calcium | >1.0 mmol/L | Essential cofactor in clotting cascade |

The simulation tracks these parameters in real-time, with laboratory results updating based on your component selections and administration timing.

Critical Decision Points

MHP simulation training challenges you with key decision points that blood bank scientists face:

O Negative vs O Positive Selection

For females of childbearing age (typically under 50), O Negative is essential to prevent Rh sensitisation. For males and post-menopausal females, O Positive may be appropriate to conserve limited O Negative stock.

Fibrinogen Replacement Timing

Early fibrinogen replacement improves outcomes. Decide between cryoprecipitate (2-3 pooled adult doses providing approximately 3-4 g fibrinogen) and fibrinogen concentrate (RiaSTAP) based on availability and clinical preference.

Component Ratio Optimisation

Evidence supports balanced transfusion with 1:1:1 ratio of red cells to FFP to platelets. Practice maintaining this ratio whilst responding to specific laboratory results.

Stock Depletion Decisions

When O Negative stock falls critically low, you must balance individual patient needs against maintaining emergency stock for potential new MHP activations. Ethical decision-making under resource constraints.

Crossmatch Method Selection

With a negative antibody screen and confirmed blood group, electronic issue provides rapid compatible blood. Positive antibody screens require serological crossmatching, adding time but ensuring safety.

Emergency to Crossmatched Blood Transition

Decide when to switch from emergency O Negative/Positive to fully crossmatched group-specific blood. Balance speed against the benefits of ABO-identical transfusion.

Scoring and Assessment

Your MHP simulation performance is assessed across six categories totalling 100 points:

Activation Speed (15 points)

How quickly you respond to MHP activation, initial blood release, and establishing communication with clinical teams.

Component Selection (25 points)

Appropriate product selection, correct doses, and maintaining balanced transfusion ratios. Points deducted for inappropriate components or missed replacement needs.

Safety Checks (20 points)

Patient identification verification, sample acceptance criteria, labelling accuracy, and traceability documentation.

Communication (20 points)

Clear communication with clinical teams, accurate time estimates, escalation of stock concerns, and handover quality.

Clinical Decisions (15 points)

Evidence-based decisions on crossmatch methods, O Negative conservation, fibrinogen timing, and transition to group-specific blood.

Documentation (5 points)

Complete and accurate record-keeping throughout the emergency.

Grading Scale:

• A Grade (90-100%) - Excellent performance demonstrating mastery
• B Grade (80-89%) - Good performance with minor improvements needed
• C Grade (70-79%) - Satisfactory performance, consider additional practice
• D Grade (60-69%) - Below expected standard, review guidelines
• F Grade (<60%) - Significant improvement required

UK Guidelines Referenced

The MHP simulation training aligns with current UK transfusion and haemorrhage management guidelines:

• BCSH Guidelines for Management of Major Haemorrhage - Core reference for blood bank protocols and target parameters
• NICE NG24 (Blood Transfusion) - Safe transfusion practice and alternatives to blood
• NICE NG39 (Major Trauma) - Assessment and initial management of major trauma patients
• JPAC Guidelines on Emergency Blood - Practical guidance for emergency transfusion situations
• RCOG Green-top Guideline 52 - Prevention and management of postpartum haemorrhage
• AAGBI Guidelines on Massive Haemorrhage - Anaesthetic perspective on blood replacement
• BSH Guidelines on Pre-Transfusion Compatibility Testing - Crossmatch method selection and electronic issue criteria

Interview Preparation Value

MHP knowledge is frequently assessed in biomedical scientist interviews, particularly for Band 5-7 blood transfusion roles:

Common Interview Questions:

• "Describe your role when MHP is activated"
• "How do you decide between O Negative and O Positive for emergency transfusion?"
• "What target parameters do you aim for during massive transfusion?"
• "How would you manage a situation where O Negative stock is critically low?"
• "Explain the different crossmatch options and when you would use each"

Competency Demonstration:

MHP simulation completion provides evidence for specialist portfolio competencies including:

• Emergency transfusion management
• Clinical decision-making under pressure
• Communication skills in critical situations
• Stock management and resource allocation
• Knowledge of current guidelines

Specialist Portfolio Evidence:

Document your simulation scores and reflective notes as evidence of emergency protocol knowledge for IBMS specialist diploma requirements.